-

Aperio Hires CAR-T Trials Expert Jonathan Yusi to Support Cell and Gene Therapy Studies

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aperio Clinical Outcomes, a leading clinical research organization (CRO), announced today that Jonathan Yusi, an expert in the coordination and management of cell and gene therapy clinical trials, has joined the company as Senior Clinical Trials Manager to support their biotechnology clients in the immuno-oncology space.

Yusi has been managing immune-based therapy trials for over seven years. Prior to joining Aperio, he was a program manager for CAR-T studies and oversaw the first CAR-T program at a large CRO. He has provided independent trial management consulting for CAR-T trials, and his expertise has resulted in lasting KOL relationships within the immuno-oncology space. In addition to his adoptive cell therapy knowledge, Yusi brings over 20 years of clinical research experience to Aperio, with a focus on trial logistics, management, and monitoring of targeted and immune therapies in oncology trials.

Says Suzanne Kincaid, Aperio’s COO and an oncology industry veteran herself, “FDA expects to see over 200 INDs for cell and gene therapies in 2020, so it is imperative that our biotech clients have expertise like Jonathan’s to manage their trials. He has a strong understanding of the complexities of cell and gene therapy studies and can break down the components for ideal study set-up. We are so excited to have Jonathan help our immuno-oncology clients as they explore these groundbreaking treatments.”

“Cell and gene therapy trials are a logistical maze, and one missed endpoint can be catastrophic to the study,” says Yusi. “These programs allow me to utilize everything I’ve learned about clinical research and oncology, and my medical and scientific background brings an understanding to the science behind the treatments. The bulk of my career has involved oncology trials, so as the treatments have evolved and become more personalized, my experience has evolved as well. These are life-saving breakthroughs, and I’m happy to bring this experience to Aperio and our immune-based therapy clients.”

About Aperio Clinical Outcomes

In a data driven industry, Aperio remains dedicated to transparency with clients and focused on the most important part of the process: people. Aperio provides full, customizable clinical research services across multiple therapeutic areas, as well as consulting services in Quality Assurance, Strategic Resourcing and Clinical Trial Technology. For more information: www.aperioclinical.com.

Contacts

Heather Newbold: +1 919-604-5704
heather.newbold@aperioclinical.com

Aperio Clinical Outcomes


Release Summary
Aperio Hires CAR-T Trials Expert Jonathan Yusi to Support Cell and Gene Therapy Studies
Release Versions

Contacts

Heather Newbold: +1 919-604-5704
heather.newbold@aperioclinical.com

Social Media Profiles
More News From Aperio Clinical Outcomes

Aperio Continues Growth with Appointment of Eric Ross as Chief Commercial Officer

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aperio Clinical Outcomes, a prominent data focused clinical research organization (CRO), appoints Eric Ross as Chief Commercial Officer, as the company adds additional infrastructure to support continued growth. Mr. Ross has served as Aperio’s VP, Business Development for the past two years as the company increased and expanded their market presence, revenues, and client base. Ross has over 18 years of experience in life sciences, including current...

Aperio Poised for Strategic Growth; Appoints Eric Ross as Vice President of Business Development

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Eric Ross has joined Aperio as VP Business Development to drive oncology and CNS growth and strengthen existing client relationships....

Aperio Relocates to the Innovating American Tobacco Campus in Downtown Durham

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aperio Clinical Outcomes has relocated its headquarters to the American Tobacco Campus, a hub for innovation in downtown Durham, NC....
Back to Newsroom